Cargando…
Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models
BACKGROUND: Non–small-cell lung cancer (NSCLC) is categorized into various histologic subtypes that play an important role in prognosis and treatment outcome. We investigated the antitumor activity of motesanib, a selective antagonist of vascular endothelial growth factor receptors (VEGFR) 1, 2, and...
Autores principales: | Coxon, Angela, Ziegler, Beth, Kaufman, Stephen, Xu, Man, Wang, Hongyu, Weishuhn, Dawn, Schmidt, Joanna, Sweet, Heather, Starnes, Charlie, Saffran, Douglas, Polverino, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515409/ https://www.ncbi.nlm.nih.gov/pubmed/22992329 http://dx.doi.org/10.1186/1476-4598-11-70 |
Ejemplares similares
-
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
por: De Boer, Richard H., et al.
Publicado: (2012) -
Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors
por: Caenepeel, Sean, et al.
Publicado: (2010) -
Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
por: Burris, Howard, et al.
Publicado: (2011) -
Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours
por: Price, T J, et al.
Publicado: (2008) -
Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience
por: Bass, Michael B., et al.
Publicado: (2014)